As we witness a surge in later-stage clinical trials within the gene therapy industry, the spotlight on comparability has never been brighter. That’s why we’re thrilled to announce the return of the 4th Gene Therapy Comparability Summit, taking place in Boston, MA, February 13-15.

This event is your gateway to uncovering how to implement effective comparability studies to overcome strategic and technical hurdles to expedite more gene therapy approvals.

What to expect at the 2024 meeting:

• Gain valuable insights from CSL Behring, Bayer, Ultragenyx, and other industry leaders on the transition to in-house manufacturing, effective variability management, and ensuring consistency across multiple facilities.
• Examine Sarepta’s considerations before and after receiving regulatory approval and investigate the distinctions among global regulatory agencies with insights from Novartis, Sarepta, and Adverum.
• Strengthen your analytical toolbox and enhance comparability studies through case studies and strategies to reduce variability with AskBio and BioMarin.
• Stay ahead of the latest advancements in process development for improved characterization and analysis of AAV-gene therapies, with a focus on minimizing process alterations, featuring contributions from Abbvie and Spark Therapeutics.
• Harness strategic insights from cell therapy study design, innovative analytical techniques, and regulatory expertise to enhance your gene therapy comparability protocols, supported by Novartis.

Don’t miss this unparalleled opportunity to stay at the forefront of gene therapy comparability. Join us and gain the knowledge, tools, and connections to secure your gene therapy approval.

Download the full event guide here to view the full expert speaker line up and see who else you will meet: https://ter.li/rrefvp